# Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery

> **NCT03243500** · PHASE4 · COMPLETED · sponsor: **Kasr El Aini Hospital** · enrollment: 91 (actual)

## Conditions studied

- Quality of Ocular Akinesia (Onset and Duration)

## Interventions

- **DRUG:** Atracurium
- **DRUG:** Lidocaine 2%
- **DRUG:** Bupivacaine 0.5%
- **DRUG:** hyaluronidase powder
- **PROCEDURE:** per-caruncular peribulbar injection

## Key facts

- **NCT ID:** NCT03243500
- **Lead sponsor:** Kasr El Aini Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-01
- **Primary completion:** 2016-05-01
- **Final completion:** 2016-05-01
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03243500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03243500, "Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03243500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*